Cancer

November 22, 2017

Molecular therapy for glioblastoma: A therapeutic mix encompassing Temozolomide (TMZ), 17-AAG, Simvastatin, Salinomycin, Linalool, Amitriptyline (TASSLA) inhibits the expression of JMJD6, impairs functioning of transcription elongation machinery, inhibits the proliferation of glioblastoma cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down regulation of its target gene, 22/November/2017, 6.06 am

Introduction: What they say: A study from the Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Ohio, USA shows that “Transcription elongation factors […]
November 21, 2017

Natural product-derived combinatorial therapy for therapy-resistant cancers: A therapeutic mix encompassing encompassing   β-cryptoxanthin (BCX), Sodium butyrate, Fucoxanthin, Ganetespib, Rosuvastatin and Cyclophosphamide (BCXSFGRC) inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via up regulation of its target gene, 21/November/2017, 10.49 pm

Introduction: What they say: A study from Broad Institute, Cambridge, Massachusetts, USA, Howard Hughes Medical Institute, Chevy Chase, Maryland and Department of Chemistry and Chemical Biology, […]
November 19, 2017

Natural product-based combination therapy targeting cancer stem cells in Myeloid leukaemia (ML): A therapeutic mix encompassing Artemisinin, Glimepiride, Fenofibrate and Calcitriol inhibits cytosolic aminotransferase BCAT1 expression, increases a-ketoglutarate levels, promotes degradation of HIF1a levels, increases DNA demethylase levels, promotes hypomethylation, increases the expression of tumor suppressor genes, inhibits leukaemia-initiating potential of AML cells, promotes differentiation of AML cells, and inhibits cancer progression in AML via up-regulation of its target gene, 19/November/2017, 11.41 pm

Introduction to what they say: A study from the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), 69120 Heidelberg, Germany; Division of Stem […]
October 21, 2017

Small molecule-based GPC2 pathway blockade enhances the efficacy of Cancer immunotherapy in Neuroblastoma: A therapeutic mix encompassing Salinomycin, EGCG, Temozolomide, & Magnolol [SETM] inhibits the expression of GPC2, increases IFNγ signalling, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, inhibits neuroblastoma proliferation, decreases tumor burden and increases survival via up-regulation of its target gene, 21/October/2017, 8.17 am

Introduction:What they say: A recent study from Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA […]